“...(the paper) provides clinical recommendations for prevention and treatment of the adverse metabolic effects of atypical antipsychotics.”

It focuses on a clinically important issue—the adverse metabolic effects of the newer, so-called atypical antipsychotic drugs.

The paper, which was co-written by Professor Marja-Liisa Dahl and me, is a review of the current literature in the field. It also provides clinical recommendations for prevention and treatment of the adverse metabolic effects of atypical antipsychotics.

Adverse metabolic effects of atypical antipsychotics may have a negative influence on both the antipsychotic treatment outcome as well as the physical health of the patient. Therefore, these effects have to be recognized and adequately managed. In this respect, this paper is important and well worth reading.

I became involved in psychoendocrinological research when I was an assistant physician at the Department of Endocrinology, Karolinska Hospital, Stockholm, 15 years ago. Later on, in the year 2000, I gained my doctor’s degree with a dissertation titled: "Influence of antipsychotic drugs on hormone levels." Since then, I have continued researching within this field.